Insights

Innovative Technology Topas Therapeutics utilizes a novel antigen-specific nanoparticle platform that induces immune tolerance by targeting liver sinusoidal endothelial cells, presenting an advanced approach for autoimmune disease therapies and offering opportunities for partnerships in biotech and pharmaceutical development.

Clinical Progression With an ongoing Phase 2a clinical trial evaluating TPM502 for celiac disease, Topas demonstrates active clinical advancement, indicating potential for early-stage collaborations, clinical trial services, and companion diagnostics development.

Strong Funding & Partnerships Having secured over 40 million euros in Series B financing and collaborating with industry leaders like Boehringer Ingelheim, Topas presents opportunities for co-investment, licensing, and strategic alliance discussions to expand their pipeline and technology reach.

Leadership Expansion Recent appointments of key executives such as a new CEO and Chief Medical Officer suggest a focus on scaling operations and advancing clinical programs, opening avenues for engaging with senior management for strategic business development or partnership talks.

Market Focus & Trends Targeting autoimmune conditions and leveraging immune tolerance technology positions Topas amidst growing trends for precision immunotherapies, making it a compelling partner for companies seeking innovative solutions in immune modulation and systemic tolerance treatments.

Topas Therapeutics GmbH Tech Stack

Topas Therapeutics GmbH uses 8 technology products and services including oEmbed, Element UI, Vue.js, and more. Explore Topas Therapeutics GmbH's tech stack below.

oEmbed

Dev Tools

Element UI

Javascript Frameworks

Vue.js

Javascript Frameworks

Preact

Javascript Libraries

Choices

Javascript Libraries

jQuery

Javascript Libraries

PWA

Miscellaneous

Prefix-Free

Miscellaneous

Topas Therapeutics GmbH Email Formats	Example	Percentage
Last@topas-therapeutics.com	Doe@topas-therapeutics.com	50%
Last@topas-therapeutics.com	Doe@topas-therapeutics.com	50%

Topas Therapeutics GmbH Email Formats

Example

Percentage

Last@topas-therapeutics.com

Doe@topas-therapeutics.com

50%

Last@topas-therapeutics.com

Doe@topas-therapeutics.com

50%

Frequently Asked Questions

What is Topas Therapeutics GmbH's official website and social media links?

Topas Therapeutics GmbH's official website is topas-therapeutics.com and has social profiles on LinkedIn Crunchbase.

What is Topas Therapeutics GmbH's SIC code NAICS code?

Topas Therapeutics GmbH's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Topas Therapeutics GmbH have currently?

As of December 2025, Topas Therapeutics GmbH has approximately 21 employees across 2 continents, including EuropeAsia. Key team members include Chief Executive Officer: H. F.Chief Operating Officer & Managing Director: C. S.Head Of Nanotechnology: D. S.. Explore Topas Therapeutics GmbH's employee directory with LeadIQ.

What industry does Topas Therapeutics GmbH belong to?

Topas Therapeutics GmbH operates in the Biotechnology Research industry.

What technology does Topas Therapeutics GmbH use?

Topas Therapeutics GmbH's tech stack includes oEmbedElement UIVue.jsPreactChoicesjQueryPWAPrefix-Free.

What is Topas Therapeutics GmbH's email format?

Topas Therapeutics GmbH's email format typically follows the pattern of Last@topas-therapeutics.com. Find more Topas Therapeutics GmbH email formats with LeadIQ.

How much funding has Topas Therapeutics GmbH raised to date?

As of December 2025, Topas Therapeutics GmbH has raised $21M in funding. The last funding round occurred on Jul 29, 2021 for $21M.

When was Topas Therapeutics GmbH founded?

Topas Therapeutics GmbH was founded in 2016.

Topas Therapeutics GmbH

Q: How many employees does Topas Therapeutics GmbH have currently?

Topas Therapeutics GmbH has approximately 21 employees.

Q: What technology does Topas Therapeutics GmbH use?

Topas Therapeutics GmbH's tech stack includes Preact, PHP, UIKit, RSS, Apache.

Biotechnology ResearchHamburg, Germany11-50 Employees

Topas Therapeutics is a clinical-stage biotechnology company transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology. Our antigen-coupled nanoparticle platform harnesses the tolerogenic power of the liver to treat autoimmune diseases. Our proprietary Topas Particles Conjugates target liver sinusoidal endothelial cells, a specific type of antigen-presenting cells highly effective at inducing T cell tolerance.  

With a technology adjustable to a broad spectrum of disease-relevant antigens, we have established a growing and advanced clinical pipeline to induce systemic tolerance.

To learn more visit https://topas-therapeutics.com/

Insights

Similar companies to Topas Therapeutics GmbH

AFFiRiS AG

BioNTech SE

Medicenna Therapeutics Corp.